AUSTRI
2016
AUSTRI Asthma Safety Trial
In 11,679 adolescents and adults with moderate-to-severe asthma, fluticasone-salmeterol was non-inferior for serious asthma-related events compared with fluticasone alone.
Result
Efficacy: Serious asthma-related events (death, intubation, hospitalisation)HR 1.03 (95% CI 0.64-1.66)
Below 1 favours fluticasone-salmeterol, above 1 favours fluticasone alone.
Also reported: Severe exacerbations HR 0.79 (p<0.001).
- Subtopic
- LABA safety
- Design
- Multicentre RCT
- Relevance
- Important: one of several pillars.
- Source
- Stempel DA, et al. N Engl J Med. 2016;374(19):1822-1830.doi 10.1056/NEJMoa1511049
Discussion & critique
Refuted prior LABA safety concerns when combined with ICS; FDA removed the LABA black-box warning for combination inhalers.